AU2019470001B2 - Rubidium and/or zinc compounds for treating Parkinson's and other neurodegenerative diseases - Google Patents

Rubidium and/or zinc compounds for treating Parkinson's and other neurodegenerative diseases Download PDF

Info

Publication number
AU2019470001B2
AU2019470001B2 AU2019470001A AU2019470001A AU2019470001B2 AU 2019470001 B2 AU2019470001 B2 AU 2019470001B2 AU 2019470001 A AU2019470001 A AU 2019470001A AU 2019470001 A AU2019470001 A AU 2019470001A AU 2019470001 B2 AU2019470001 B2 AU 2019470001B2
Authority
AU
Australia
Prior art keywords
asp
cells
animals
rbe
phagocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019470001A
Other languages
English (en)
Other versions
AU2019470001A1 (en
Inventor
Oleksandr Balakin
Peter Novak
Maxim TEMNIKOV
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nomax Therapeutics Inc
Original Assignee
Nomax Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nomax Therapeutics Inc filed Critical Nomax Therapeutics Inc
Publication of AU2019470001A1 publication Critical patent/AU2019470001A1/en
Assigned to Nomax Therapeutics Inc. reassignment Nomax Therapeutics Inc. Request for Assignment Assignors: VECTOR VITALE IP LLC
Application granted granted Critical
Publication of AU2019470001B2 publication Critical patent/AU2019470001B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2019470001A 2019-10-11 2019-10-11 Rubidium and/or zinc compounds for treating Parkinson's and other neurodegenerative diseases Active AU2019470001B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/055770 WO2021071499A1 (en) 2019-10-11 2019-10-11 Rubidium and/or zinc compounds for treating parkinson's and other neurodegenerative diseases

Publications (2)

Publication Number Publication Date
AU2019470001A1 AU2019470001A1 (en) 2022-05-12
AU2019470001B2 true AU2019470001B2 (en) 2024-09-19

Family

ID=68387423

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019470001A Active AU2019470001B2 (en) 2019-10-11 2019-10-11 Rubidium and/or zinc compounds for treating Parkinson's and other neurodegenerative diseases

Country Status (6)

Country Link
US (2) US11779597B2 (enExample)
EP (1) EP4041214A1 (enExample)
JP (4) JP7634895B2 (enExample)
AU (1) AU2019470001B2 (enExample)
CA (1) CA3293959A1 (enExample)
WO (1) WO2021071499A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116077524A (zh) * 2023-02-27 2023-05-09 广西馨海药业科技有限公司 氯化铷在制备治疗帕金森综合征的药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0472053A2 (en) * 1990-08-20 1992-02-26 Eisai Co., Ltd. Sulfonamide derivatives
WO2015185602A1 (en) * 2014-06-04 2015-12-10 Affiris Ag Treatment and prevention of parkinson's disease (pd)
US10226484B2 (en) * 2014-12-01 2019-03-12 Peter Y Novak Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2790926B2 (ja) * 1990-08-20 1998-08-27 エーザイ株式会社 スルホンアミド誘導体
US6162350A (en) 1997-07-15 2000-12-19 Exxon Research And Engineering Company Hydroprocessing using bulk Group VIII/Group VIB catalysts (HEN-9901)
US20160153957A1 (en) 2014-12-01 2016-06-02 Peter Y. Novak Method for diagnostics of pathology in biologocal objects
MX2018009662A (es) * 2016-02-11 2018-09-11 Chevion Mordechai Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
CN106581056A (zh) * 2016-10-11 2017-04-26 徐志强 锌在制造治疗帕金森病药物的用途
US10183041B2 (en) 2017-04-12 2019-01-22 Vector Vitale Ip Llc Antibacterial composition and its use in treating bacterial infections
US10933091B1 (en) 2019-12-20 2021-03-02 Vector Vitale Ip Llc Composition and method for the treatment of type I diabetes
US10799530B1 (en) 2019-12-20 2020-10-13 Vector Vitale Ip Llc Composition and method for the prevention and treatment of obesity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0472053A2 (en) * 1990-08-20 1992-02-26 Eisai Co., Ltd. Sulfonamide derivatives
WO2015185602A1 (en) * 2014-06-04 2015-12-10 Affiris Ag Treatment and prevention of parkinson's disease (pd)
US10226484B2 (en) * 2014-12-01 2019-03-12 Peter Y Novak Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CASACCHIA M ET AL: "Cloruro di Rubidio di Parkinson - [Rubidium chloride in Parkinson's disease: preliminary results]", ACTA NEUROLOGICA, CHIRURGIA, NAPLES, IT, vol. 30, no. 6, 1 January 1975 (1975-01-01), pages 615 - 618, *
PAUL A. ADLARD ET AL: "Metals and Alzheimer's Disease: How Far Have We Come in the Clinic?", JOURNAL OF ALZHEIMER'S DISEASE, vol. 62, no. 3, 13 March 2018 (2018-03-13), NL, pages 1369 - 1379, DOI: 10.3233/JAD-170662 *

Also Published As

Publication number Publication date
EP4041214A1 (en) 2022-08-17
JP2022551943A (ja) 2022-12-14
JP2025148408A (ja) 2025-10-07
US12036238B2 (en) 2024-07-16
AU2019470001A1 (en) 2022-05-12
CA3293959A1 (en) 2026-03-02
CA3154392A1 (en) 2021-04-15
US20240173350A1 (en) 2024-05-30
JP2024038270A (ja) 2024-03-19
US11779597B2 (en) 2023-10-10
JP7634895B2 (ja) 2025-02-25
WO2021071499A1 (en) 2021-04-15
NZ787735A (en) 2025-03-28
JP2026035686A (ja) 2026-03-04
US20230210894A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
JP5736421B2 (ja) 生理学的過程の調節およびこれに有用な薬剤
ES2685947T3 (es) Agentes antienvejecimiento
Guo et al. Anti-fibrotic effects of puerarin on CCl4-induced hepatic fibrosis in rats possibly through the regulation of PPAR-γ expression and inhibition of PI3K/Akt pathway
US8318812B2 (en) Therapeutic agents for the treatment of lymphoid malignancies
JP7267546B2 (ja) アミノ酸組成物及びその使用
US6174875B1 (en) Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
JP2018021033A (ja) ペプチド治療薬およびその使用方法
CA2396533A1 (en) Treatment of ischemic brain injuries with brain targetted antioxidant compounds
Saadi et al. Spatial, temporal, and cell-type-specific expression of NADPH Oxidase isoforms following seizure models in rats
Shen et al. SIRT3-mediated deacetylation of SDHA rescues mitochondrial bioenergetics contributing to neuroprotection in rotenone-induced PD models
EP2863935B1 (en) Interval therapy for the treatment of loss of eyesight in humans with glaucoma
JP2026035686A (ja) パーキンソン病およびその他の神経変性疾患を処置するためのルビジウムおよび／または亜鉛化合物
WO2022184091A1 (zh) 透明质酸在用于制备预防或治疗铁死亡相关疾病的药物中的应用
JP2022541720A (ja) 細胞外小胞に含まれるｅｎａｍｐｔの産生および使用
EP2397144A1 (en) Use of Isoacteoside in Preventing or Treating Amyloid Beta Peptide-Associated Diseases or Conditions, and Method for Inhibiting Formation, Accumulation or Aggregation of Amyloid Beta Peptides
US9029419B2 (en) Use of zinc N-acetyltaurinate
WO2019040359A1 (en) COMPOSITIONS AND METHODS FOR PROTECTING MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESS
US20210000877A1 (en) Method For Upregulation Of Thioredoxin Expression In Stem Cells
TWI722492B (zh) 含蓮蓬萃取物之組合物及其用於治療頭頸癌症之用途
Wang et al. Activation of SIRT3 alleviates neurodegeneration via rescuing mitochondrial succinate dehydrogenase activity and bioenergy supply in rotenone-induced PD models
US20230255916A1 (en) Amino acid compositions and uses thereof
RU2744453C2 (ru) Таргетная неинвазивная трансплантация в мозг функционально активных митохондрий для лечения нейродегенеративных заболеваний
WO2025046207A1 (en) New use of a pde 5 inhibitor combination in promoting neurite outgrowth
KR20050031692A (ko) 메페남산을 함유하는 치매 예방 및 치료용 약제 조성물

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NOMAX THERAPEUTICS INC.

Free format text: FORMER APPLICANT(S): VECTOR VITALE IP LLC

FGA Letters patent sealed or granted (standard patent)